28 related articles for article (PubMed ID: 33826578)
1. Comparison of 68Ga-PSMA PET/CT and Contrast-Enhanced MRI on Residual Disease Assessment of Juvenile Nasal Angiofibroma.
Thakar A; Sakthivel P; Prashanth A; Bhalla AS; Sharma SC; Kumar R
Clin Nucl Med; 2020 Apr; 45(4):308-309. PubMed ID: 32049728
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Prostate-Specific Membrane Antigen PET/CT and Contrast-Enhanced Magnetic Resonance Imaging in Follow-up Assessment of Juvenile Nasal Angiofibroma-A Novel Pilot Study.
Thakar A; Sakthivel P; Arunraj ST; Bhalla AS; Kakkar A; Kumar R; Kumar R
Clin Nucl Med; 2020 Dec; 45(12):e498-e504. PubMed ID: 33065615
[TBL] [Abstract][Full Text] [Related]
3. Negative 68Ga-Prostate-Specific Membrane Antigen PET/CT Scan on a Recurrent Juvenile Nasopharyngeal Angiofibroma.
Chandran A; Verma H; Bhalla AS; Kumar R; Kakkar A
Clin Nucl Med; 2022 Mar; 47(3):e268-e270. PubMed ID: 35020647
[TBL] [Abstract][Full Text] [Related]
4. Fusion 68Ga-Prostate-Specific Membrane Antigen PET/MRI on Postoperative Surveillance of Juvenile Nasal Angiofibroma.
Sakthivel P; Thakar A; Arunraj ST; Bhalla AS; Kumar R
Clin Nucl Med; 2020 Jul; 45(7):e325-e326. PubMed ID: 32404701
[TBL] [Abstract][Full Text] [Related]
5. Advantage of 68Ga-PSMA PET/CT on Postradiotherapy Response Assessment of Juvenile Nasal Angiofibroma.
Sakthivel P; Thakar A; Thankarajan Arunraj S; Bhalla AS; Kumar R
Clin Nucl Med; 2021 Feb; 46(2):e123-e124. PubMed ID: 33156054
[TBL] [Abstract][Full Text] [Related]
6. Pterygoid Base Pneumatization Simulating Residual Disease-A Pitfall of Structural Imaging in Juvenile Nasal Angiofibroma.
Sakthivel P; Thakar A; Verma H; Bhalla AS; Arunraj ST; Kumar R
Clin Nucl Med; 2021 Oct; 46(10):e496-e497. PubMed ID: 33826578
[TBL] [Abstract][Full Text] [Related]
7. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
Eissa A; Elsherbiny A; Coelho RF; Rassweiler J; Davis JW; Porpiglia F; Patel VR; Prandini N; Micali S; Sighinolfi MC; Puliatti S; Rocco B; Bianchi G
Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244
[TBL] [Abstract][Full Text] [Related]
8. PET/CT With
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673
[TBL] [Abstract][Full Text] [Related]
9. The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.
Hoffmann MA; Wieler HJ; Baues C; Kuntz NJ; Richardsen I; Schreckenberger M
Urology; 2019 Aug; 130():1-12. PubMed ID: 30986486
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer.
Afaq A; Bomanji J
Br Med Bull; 2018 Dec; 128(1):37-48. PubMed ID: 30272121
[TBL] [Abstract][Full Text] [Related]
11. Performance of
Bailey J; Piert M
Curr Urol Rep; 2017 Sep; 18(11):84. PubMed ID: 28889366
[TBL] [Abstract][Full Text] [Related]
12. Performance of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in the diagnosis of primary prostate cancer: a systematic review and meta-analysis.
Hu X; Wu Y; Yang P; Wang J; Wang P; Cai J
Int Braz J Urol; 2022; 48(6):891-902. PubMed ID: 34003611
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
